Covid-19, Ema presenterà decisione su pillola Merck il prima possibile Da Reuters

da Redazione



© Reuters. La sede centrale dell’Agenzia europea per i medicinali ad Amsterdam, in Olanda. REUTERS/Piroschka van de Wouw

(Reuters) – L’Agenzia europea per il farmaco ha detto che deciderà se raccomandare l’uso a livello continentale della pillola antivirale contro il Covid-19 sviluppata da Merck & Co. e Ridgeback Biotherapeutics nel minor tempo possibile.

L’Ema ha aggiunto che la revisione dei dati disponibili è ora in corso, con l’agenzia impegnata per aiutare gli stati membri prima di una possibile approvazione.

(Tradotto a Danzica da Enrico Sciacovelli, in redazione a Milano Gianluca Semeraro, enrico.sciacovelli@thomsonreuters.com, +48587696613)

Responsabilità: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.





Fonte

0 commento
0

You may also like

Lascia un Commento